Akers Biosciences, Inc. (AKER)
Chart Events
Performance Outlook
| Previous Close | 2.6400 |
| Open | 2.6500 |
| Bid | 2.4800 x 900 |
| Ask | 2.7800 x 800 |
| Day's Range | 2.4700 - 2.8400 |
| 52 Week Range | 1.5500 - 8.8500 |
| Volume | 536,366 |
| Avg. Volume | 857,066 |
| Market Cap | 45.795M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.2600 |
| Earnings Date | Mar 31, 2021 - Apr 05, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
- PR Newswire
INVESTIGATION ALERT: Halper Sadeh LLP Investigates the Following Companies on Behalf of Shareholders - PAND, PRAH, AEGN, PTVCA, CRHM, CBLI, AKER
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
- ACCESSWIRE
STOCKHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following Merger
NEW YORK, NY / ACCESSWIRE / February 24, 2021 /Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating: * Cleveland BioLabs, Inc. (NASDAQ:CBLI) relating to the creation of a combined company between the Company and Cytocom, Inc.
- Business Wire
MyMD Pharmaceuticals Announces New Data on Its Lead Compound MYMD-1 from a Phenotypic Study Performed by Eurofins Discovery
Akers Biosciences, Inc. (Nasdaq: AKER), with its proposed merger partner MyMD Pharmaceuticals, Inc. ("MyMD"), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced new data from a study conducted by Eurofins Discovery Phenotypic Center of Excellence.
